Negative Regulation of CD95 Ligand Gene Expression by Vitamin D$_3$ in T Lymphocytes

Marco Cippitelli, Cinzia Fionda, Danilo Di Bona, Francesca Di Rosa, Aldo Lupo, Mario Piccoli, Luigi Frati and Angela Santoni

*J Immunol* 2002; 168:1154-1166; doi: 10.4049/jimmunol.168.3.1154
http://www.jimmunol.org/content/168/3/1154

**References**
This article cites 69 articles, 34 of which you can access for free at:
http://www.jimmunol.org/content/168/3/1154.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Negative Regulation of CD95 Ligand Gene Expression by Vitamin D₃ in T Lymphocytes

Marco Cippitelli, Cinzia Fionda, Danilo Di Bon, Francesca Di Rosa, Aldo Lupo, Mario Piccoli, Luigi Frati, and Angela Santoni

As ligand (also called CD95L or FasL), a type II transmembrane protein that induces programmed cell death (apoptosis) by binding to its receptor Fas (also called CD95/Apo-1), is an important molecule implicated in the activation-induced cell death (AICD) of T lymphocytes, the maintenance of immunologically privileged anatomical sites, and the CTL and NK cell-mediated cytotoxicity against a variety of tumor and virus-infected cells (1–3).

Moreover, aberrant expression of Fas and FasL has been involved in diseases in which the peripheral lymphocyte homeostasis is compromised. Mutations of the genes encoding Fas or FasL (the mutations are termed lpr and gld, respectively) give rise to fatal autoimmunity and lymphadenopathy, and individuals bearing heterozygous mutations in the fas or the fasL gene develop severe autoimmune lymphoproliferative syndromes (4, 5).

Recently, a number of studies have significantly improved the knowledge of the pathophysiological role of Fas and FasL in vivo, particularly in the induction and regulation of several organ-specific autoimmune diseases. In this regard, an improperly regulated Fas/FasL system could become a serious danger for the organism, leading to selective destruction of target cells within a tissue. This process has been well documented in animal models of experimental allergic encephalomyelitis (EAE), or autoimmune diabetes, in which the initial specific cell damage is mediated by tissue-infiltrating FasL/T lymphocytes (6, 7).

Although FasL has been extensively studied for its role in delivering apoptotic signals through its receptor Fas on sensitive target cells, experimental evidence has also revealed a second role as a reverse signaling activating receptor in T cells. In fact, similarly to the previously described dual-direction signaling for different TNF superfamily of ligand-receptor pairs, such as CD27L, CD30L, OX40L, and CD40L (8, 9), triggering of FasL is required for CTLs to achieve an optimal proliferation. In this context, a further level of activation and fine regulation during an immune response is also given by the ability of the activated Fas receptor to induce phenotypical and functional maturation of dendritic cells (DC), secretion of proinflammatory cytokines such as IL-1β and TNF-α, and preferential T cell polarization into a Th1 phenotype (10).

The 1,25(OH)₂D₃ (Calcitriol, the biologically active metabolite of vitamin D₃) is a secosteroid hormone that binds and activates...
the nuclear vitamin D3 receptor (VDR), belonging to the superfamily of steroid and thyroid hormone receptors (11, 12). The classical functions of 1,25(OH)2D3 include regulation of calcium absorption in the intestine, maintenance of mineral homeostasis in the kidney, and regulation of bone remodeling (11, 12). Nevertheless, 1,25(OH)2D3 also functions as a regulator of the hematopoietic system, as it modulates lymphocyte activation and proliferation. Induces the differentiation of promyelocytes into monocytes, and inhibits secretion of several cytokines in T cells (13, 14). Furthermore, 1,25(OH)2D3 inhibits differentiation, activation, and survival of DC, thus contributing to decrease DC-dependent T cell activation and to suppress immune response (15, 16).

The immunosuppressive activity of 1,25(OH)2D3 and its analogues has been studied in different models of autoimmune diseases and in experimental organ transplantation (17). Administration of 1,25(OH)2D3 can greatly reduce the severity of EAE, an animal model of the multiple sclerosis (MS) (18–20), prevent systemic lupus erythematosus in lpr/lpr mice (21), and ameliorate autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice in combination with cyclosporin A (CsA) (22).

We and others have recently described the molecular mechanisms responsible for the negative regulation of the IFN-γ and IL-12 genes, by 1,25(OH)2D3/VDR in activated T lymphocytes and macrophages/DC (23, 24).

In this study, we describe the effect of 1,25(OH)2D3 on the activation of the fasL gene in T lymphocytes and the regulatory action of the 1,25(OH)2D3-activated VDR on the human fasL promoter. We show that 1,25(OH)2D3 suppresses AICD and fasL mRNA expression in the activated 2B4.11 T cell hybridoma. We also demonstrate that the PMA plus ionomycin-stimulated fasL promoter activity is inhibited by 1,25(OH)2D3 in 2B4.11 cells, and in Jurkat cells cotransfected with a human VDR expression vector. The inhibition is dependent on the presence of an intact VDR DNA-binding domain (DBD) and ligand-dependent transcriptional activation domain (AF-2), and the cotransfection of retinoid X receptor (RXR) enhances this effect. Moreover, by progressive deletions of the fasL promoter, we delineated a minimal region containing the transcription start site and a noncanonical c-Myc-binding element that mediates the repression (25). The data presented in this work place FasL as a novel target for the different immunoregulatory activities of 1,25(OH)2D3. The physiological and pharmacological implications of these observations are discussed.

Materials and Methods

Cell lines and reagents

Jurkat cells, 2B4.11 murine T hybridoma cells, and P815-Fas mastocytoma cells were maintained as described previously (23). PMA and ionomycin were purchased from Sigma-Aldrich (St. Louis, MO). The 1,25(OH)2D3 and CsA were purchased from Biomol (Plymouth Meeting, PA).

Assessment of cell viability and apoptosis

For the induction of apoptosis, 2B4.11 cells (5 × 10⁶/ml) were cultured in 24-well plates. Triplicate samples were stimulated with 20 ng/ml PMA and 0.5 μg/ml ionomycin in the absence or in the presence of the indicated amount of 1,25(OH)2D3 or 200 ng/ml CsA, for 24 h in complete medium. Cells were harvested and viability was assessed by addition of 5 μg/ml propidium iodide (PI; Sigma-Aldrich) and immediate analysis by a FACScan flow cytometer (BD Biosciences, Mountain View, CA). Dead cells were quantified as those taking up the dye. Apoptosis assay was performed by annexin V staining of the translocated phosphatidylserine, from the inner side of the plasma membrane to the outer layer during the early stages of apoptosis (26). Triplicate samples of 2B4.11 cells (5 × 10⁶/ml) were cultured in 24-well plates and stimulated with 20 ng/ml PMA and 0.5 μg/ml ionomycin in the absence or in the presence of 20 nM of 1,25(OH)2D3 or 200 ng/ml CsA, for 5 h in complete medium. Cells were then stained using an Annexin VFITC kit (Bender MedSystems, Vienna, Austria) following the manufacturer’s instructions and immediately analyzed by a FACScan flow cytometer (BD Biosciences).

Northern blot analysis

Total RNA was extracted from 2B4.11 hybridoma T cells by TRizol (Life Technologies, Grand Island, NY). The cells were untreated or stimulated with 20 ng/ml PMA and 0.5 μg/ml ionomycin in the absence or in the presence of 20 nM of 1,25(OH)2D3 for 5 h. Equal amounts of RNA (15 μg/lane) were fractionated on a 1.5% agarose-formaldehyde gel. The specific mRNA was detected by hybridization of S&S Nytran membranes (Schleicher & Schuell, Keene, NH) with a 32P-labeled cDNA probe for murine FasL. Total RNA-containing membranes were prehybridized for 2 h at 65°C in the QuikHyb Hybridization Solution (Stratagene, La Jolla, CA). The membranes were then washed twice in 2× SSC containing 0.1% SDS and twice in 0.1× SSC containing 0.1% SDS at 60°C (20 min each time), and exposed to X-Omat AR films (Eastman Kodak, Rochester, NY) at −70°C with intensifying screens. The probe for murine FasL was generated by RT-PCR according to standard methods, on total RNA extracted from 2B4.11 cells activated for 3 h with PMA plus ionomycin. Primers used for amplification: FasL forward, 5′-CAGCCTTCTCACCTGCAAGAG-3′; FasL reverse, 5′-AGATTCCCTAAAATGATCAAGAGAG-3′.

Cytotoxicity assay

Fas-transfected P815 mastocytoma cells (10⁶ cells; kindly provided by R. De Maria, ISS, Rome, Italy) were labeled with 0.2 μCi of 31Cr (Amer sham, Arlington Heights, IL) at 37°C. A total of 2 × 10⁵ target cells was cocultured with 2B4.11 effector cells in 200 μl of complete medium in U-bottomed 96-well plates for 5 h. The 2B4.11 effector cells were previously activated with 20 ng/ml PMA and 0.5 μg/ml ionomycin in the absence or in the presence of 20 nM 1,25(OH)2D3 or 200 ng/ml CsA, for 4 h in complete medium. Cells were then harvested, washed twice in complete medium, and cocultured with 31Cr-labeled target cells. After 4 h, 100 μl of supernatant was removed from each well and counted in a gamma counter for 31Cr release determination. Maximal and spontaneous release was determined by incubating 31Cr-labeled target cells with 1% Nonidet P-40 or medium alone, respectively. Percent specific killing was calculated as 100% (experimental 31Cr release — spontaneous 31Cr release)/(maximal 31Cr release — spontaneous 31Cr release). All determinations were made in triplicate, and E/T ratios ranged from 80:1 to 20:1, as indicated.

Plasmid constructions

The human FasL promoter luciferase reporter pFaSL-486, the distal and proximal NF-AT-binding mutants (ΔNF-AT-Dist. and ΔNF-AT-Prox.), the RE3/FLR-binding mutant, the 3XNF-AT-distal, and the 3XRE3/FLRE triplicated copies constructs of the indicated FasL promoter enhancers were kindly provided by G. A. Koretzky (Department of Internal Medicine, Iowa City, IA). To prepare the human FasL promoter, the pFaSL-486Gal, the appropriate FasL promoter fragment was subcloned into the HindIII site of the promotorless pE3Q β-Gal reporter vector. The different deletions of the human FasL promoter — 453 FaSLpG2L2, −373 FaSLpG2L, −318 FaSLpG2L, −237 FaSLpG2L2, and −195 FaSLpG2L2 were kindly provided by C. V. Paya (Mayo Clinic, Rochester, MN). The CMV-β-Gal expression vector pE3Q76 was kindly provided by C. B. Wilson (Department of Pediatrics and Immunology, University of Washington, Seattle, WA). To prepare the Rous sarcoma virus (RSV) 3′-luc expression vector, a HindIII-Xbal fragment containing the complete luciferase-coding region was digested from the pGL3 basic luciferase vector (Promege, Madison, WI) and cloned into the pRCR SV expression vector (Invitrogen, San Diego, CA). To prepare the RSV-Gal expression vector, a Sall-HindIII fragment containing the 234 FasLTR (long terminal repeat) was digested from the pREP7 expression vector (Invitrogen) and cloned into the promotorless pE3Q β-Gal reporter vector. Expression vectors for wild-type human VDR pCMV- hVDR, and VDR DBD mutants pCMV-hVDR (EGG-GSV), pCMV-hVDR (R50G), and the pCMV- VDRF (VDRF; residues 14–114 of the VDR DBD) were kindly provided by L. Freedman (Memorial Sloan-Kettering Cancer Center, New York, NY). Expression vectors for wild-type human VDR pSG5-VDR and for VDR AF-2 domain point mutants pSG5- VDR (L147→A) and pSG5-VDR(E420→A) were kindly provided by M. R. Haussler (Department of Biochemistry, University of Arizona, Tucson, AZ). The expression vector for human VDR helix 3 domain point mutant K246A, pSG5VDR(K246A) and for VDR AF-3 domain point mutants pSG5- VDR (K246A) were kindly provided by R. Aranda (Universidad Autonoma de Madrid, Madrid, Spain). Expression vectors for wild-type human and murine RXRα and for C-terminal deletion mutants of murine RXRα (dominant-negative mutants: mRXRαT1 truncated at aa 448, and RXRαT2 truncated at aa 454) were kindly provided by P. Chambon (Centre National de la Recherche Scientifique-Institut National de la Sante et de la Recherche...
VITAMIN D₃ MODULATES FasL TRANSCRIPTION

Medicale-Université Louis Pasteur, Illkirch Cedex, France). The CMV and RSV-driven expression vectors for human c-Myc (pcDNA3cMyc) and c-Rel (pRSV-Rel) were provided by G. Zupi (Regina Elena Cancer Institute, Rome, Italy) and H. A. Young (National Institutes of Health, Frederick, MD), respectively.

DNA transfections
Transfections of Jurkat cells were conducted by the DEAE-dextran method, as already described (23). To decrease variations in the experiments due to different transfection efficiency, cells were transfected in single batches that were then separated into different drug treatment groups. A CMV-β-Gal or RSV-Gal (for luciferase assays) or RSV-luc (for β-galactosidase assays) expression vector was cotransfected to normalize DNA uptake. After 24 h, cells were treated with different combinations of stimuli and, after additional 24 h, cells were harvested and protein extracts were prepared for the β-galactosidase and luciferase assays, by four cycles of rapid freezing and thawing, followed by centrifugation at 14,000 rpm (4°C) for 15 min. Protein concentration was quantified by the bicinchoninic acid method (Pierce, Rockford, IL). Luciferase activity was read using the luciferase assay system (Promega, Madison, WI) following the manufacturer’s instructions. β-galactosidase activity was determined spectrophotometrically at 570 nm by the hydrolysis of chlorophenol red β-D-galactopiranoside, as described previously (23). The 2B4.11 murine T hybridoma cells were transfected as described for Jurkat cells, using 150 μg/ml DEAE-dextran. After 24 h, cells were treated with different combinations of stimuli for additional 8 h and then processed as described above.

EMSA
Nuclear proteins were prepared as described previously (23). Protein concentration of extracts was determined by the bicinchoninic acid method (Pierce, Rockford, IL). Approximately 5–10 μg nuclear proteins was used in these experiments as a control for effective repression. Nuclear protein complexes were resolved by electrophoresis on 5% nondenaturing polyacrylamide gels in 0.5× TBE buffer at 12 V/cm for 2 h at room temperature. Dried gels were exposed to Kodak XAR-5 film (Eastman Kodak) at −70°C with intensifying screens. Oligonucleotides were synthesized by the phosphoramidite method on a DNA/RNA synthesizer (Applied Biosystems, Foster City, CA; model 392). Complementary strands were denatured at 90°C for 5 min and annealed at room temperature. The double-strand probes were end labeled using Klenow fragment (Life Technologies) and [α-32P]dCTP (Amersham). Unincorporated [α-32P]dCTP was removed by chromatography through a G-25 spin column (Boehringer Mannheim, Mannheim, Germany). Approximately 3 × 10⁶ cpm of labeled DNA was used in a standard EMSA reaction. In supershift analysis, the Ab was added to the binding reaction and the mixture was incubated for 30 min at room temperature before adding the labeled DNA probe. The Ab against Gαs (clone 9A7, a rat mAb) was purchased from Biomol. The Ab against c-Jun (rabbit polyclonal corresponding to the conserved residues 247–263 of the protein; Santa Cruz Biotechnology, Santa Cruz, CA) was used as a nonspecific Ab. The following double-strand oligomers were used as specific labeled probes or cold competitors: FasL-NF-κB prox. (human FasL gene, −162 to −135 bp), 5′-AGACAGAGGTGTTCCTCCGTAGCTGGA-3′; FasL-Myc-RE (human Fas gene, −139 to −110 bp), 5′-ATGGAAACCTTATAAGAGGAGATCCAGCTTGTGGA-3′; consensus Myc, 5′-gatcCCTCCACACTCCCGGAGAGGAGGAGGAGGAGGGGCGA-3′; mVDRE (mouse osteopontin gene), 5′-gatcTCGCCGGTGTAAGCGGGGCCAGCA-3′; mVDRE (mouse osteopontin gene), 5′-gatcCAGAGGTTCACTCGCGC-3′; NF-κB (IκB-1 LTR, −107 to −91 bp), 5′-gatcAATACTCAGTTGGCTTC-3′; OCT (human histone H2b, −60 to −35), 5′-gatcCTCCCACCTTTTTCGCTGAT-3′, was used as a nonspecific competitor.

Results
1,25(OH)₂D₃ inhibits AICD in 2B4.11 murine T cell hybridoma
In T lymphocytes, fasL mRNA expression is induced by TCR-mediated activation or by stimuli such as phorbol ester plus a Ca²⁺ ionophore that bypass TCR signaling (27). Recent studies with the fasL promoter have identified several enhancer elements that cooperate in the transcription of this gene in activated T cells. Among these, NF-AT, early growth response (EGR) 2/3, and c-Myc play an absolutely necessary role in this process (25, 28–33). In T lymphocytes, induction of fasL mRNA is inhibited by a number of immunomodulators such as CsA that inhibits the activation of the NF-AT and EGR-2/3 transcription factors, or TGF-β1 that inhibits c-Myc expression (30, 31, 34). In addition, ligand-mediated activation of different nuclear hormone receptors such as glucocorticoid receptor (GR) or retinoic acid receptors (RAR/RXR), which prevent AICD, also inhibits up-regulation of FasL in T lymphocytes (35–38).

To investigate whether 1,25(OH)₂D₃ could interfere with the AICD and fasL gene expression in activated T lymphocytes, 2B4.11 T cells were activated with PMA plus ionomycin in the presence or absence of increasing concentrations of hormone, and cell viability and apoptosis were measured by PI uptake or annexin V/PI staining, followed by FACS analysis. As shown in Fig. 1A, activation of 2B4.11 T cells by the combination of PMA plus ionomycin for 24 h resulted in significant (~50%) cell death, which was almost completely inhibited by the presence of CsA (used in these experiments as a control for effective repression). The AICD of 2B4.11 cells significantly decreased in the presence of increasing concentrations of 1,25(OH)₂D₃ in a dose-dependent fashion (Fig. 1B); apoptosis assays performed by annexin V staining of early stage apoptotic cells confirmed inhibition of AICD, with a ~50% reduction after 5 h PMA plus ionomycin activation in the presence of 20 nM of 1,25(OH)₂D₃ (Fig. 1C, panel c). Treatment of 2B4.11 cells with 1,25(OH)₂D₃ alone did not alter cell viability or growth in our assays (data not shown).

1,25(OH)₂D₃ inhibits fasL gene expression and Fast-mediated target lysis by activated 2B4.11 T cells
Previous studies have demonstrated that AICD in 2B4.11 T cell hybridoma proceeds via expression of FasL and subsequent Fas/FasL interaction (39). To determine whether one of the mechanisms of 1,25(OH)₂D₃-mediated inhibition of AICD could be direct interference with fasL gene expression, total RNA was isolated from 2B4.11 cells at 5 h after activation in the presence of 20 nM of 1,25(OH)₂D₃ and analyzed for fasL mRNA expression by Northern blot assay. As shown in Fig. 2A, fasL mRNA was induced by PMA plus ionomycin stimulation, and inhibited by the presence of 20 nM of 1,25(OH)₂D₃, indicating that FasL is a molecular target of this hormone.

To further verify the functional consequences of 1,25(OH)₂D₃ on FasL expression, a cytotoxicity assay using 53Cr-labeled Fas-transfected P815 target cells was performed. As shown in Fig. 2B, activation of 2B4.11 cells in the presence of 20 nM of 1,25(OH)₂D₃ significantly decreased specific killing, when compared with the cytotoxicity of 2B4.11 cells activated in the absence of hormone. The effect of CsA (used in these experiments as a control for effective repression) is also shown in the figure.

Thus, AICD, activation-induced fasL mRNA expression, and cytotoxicity of Fas-transfected targets are inhibited by 1,25(OH)₂D₃ in T cells, as previously shown for other modulators such as glucocorticoids and retinoids (35–38).

1,25(OH)₂D₃ modulates fasL promoter activity in activated T cells
Ligand-activated nuclear hormone receptors, such as GR and RAR/RXR, act as powerful immunomodulators and repress different cytokine genes through negative interference with a number of transcriptional factors important for specific enhancer activity (40–44). In this regard, a number of experimental data have clearly shown that 1,25(OH)₂D₃ can repress transcription and expression of several cytokines by directly modulating the activity.
DNA binding, and/or the expression of different transcription factors such as NF-AT, NF-κB, or c-Myc in activated T lymphocytes (23, 24, 45–49). To determine whether one of the mechanisms involved in 1,25(OH)₂D₃-mediated inhibition of the fasL gene activation could be direct interference with the transcriptional activity of its promoter, transient transfection assays were performed in

**FIGURE 1.** The 1,25(OH)₂D₃ represses AICD in 2B4.11 T cell hybridoma. A and B, 5 × 10⁵/ml 2B4.11 hybridoma cells were stimulated in triplicate with 20 ng/ml PMA and/or 0.5 μg/ml ionomycin in the absence or in the presence of 200 ng/ml CsA, or the indicated concentration of 1,25(OH)₂D₃. Twenty-four hours after stimulation, cells were harvested and viability was assessed by PI uptake and immediate analysis by a flow cytometer. Results are expressed as percentage of apoptosis, and represent the mean value (X ± SE) from at least four experiments. C, 2B4.11 hybridoma cells were stimulated as described above for 5 h, in the absence or in the presence of 20 nM of 1,25(OH)₂D₃, or 200 ng/ml CsA. The cells stained with Annexin-V-FITC single positive (lower right) and PI/Annexin V-FITC double positive (upper right) are early and late phase apoptotic cells, respectively. a, Unstimulated cells. b, Five-hour PMA plus ionomycin. c, Five-hour PMA plus ionomycin plus 20 nM 1,25(OH)₂D₃. d, 5-h PMA plus ionomycin plus 200 ng/ml CsA. Percentage of single- and double-positive cells is displayed in each panel (lower right and upper right quadrants). The experiment shown in the figure is representative of four independent experiments, all displaying similar results.
Fas L-mediated target lysis. Vitamin D₃ shown in the 1,25(OH)₂D₃-treated 2B4.11 cells, but not in Jurkat cells (Fig. 3, B). These data are substantiated by the expression level of VDR in these cells, as detected in EMSA. A specific binding of complexes containing VDR to a consensus VDRE (mVDRE (mouse) in these cells, as described in Fig. 1, was shown in the figure is representative of three independent experiments, all displaying similar results. B, ⁵¹Cr-labeled P815-Fas target cells were incubated for 5 h with 2B4.11 effector cells previously activated as indicated in the figure, to induce Fas/FasL-dependent lysis. One experiment representative of three is shown.

2B4.11 and Jurkat T cells. As shown in Fig. 3A, PMA plus ionomycin treatment of 2B4.11 cells induces activation of a human fasL promoter fragment consisting of 486 bp immediately 5’ of the translational start site (50), and the presence of 20 nM of 1,25(OH)₂D₃ significantly represses (~40–50%) the promoter activity. On the contrary, 1,25(OH)₂D₃ does not repress activation of the fasL promoter in Jurkat cells (Fig. 3B), indicating that the Jurkat cells used in this study are resistant to 1,25(OH)₂D₃ treatment (23). These data are substantiated by the expression level of VDR in these cells, as detected in EMSA. A specific binding of complexes containing VDR to a consensus VDRE (mVDRE (mouse osteopontin gene)) was detected only in nuclear extracts of 1,25(OH)₂D₃-treated 2B4.11 cells, but not in Jurkat cells (Fig. 3, C and D), indicating that expression of VDR correlates with repression of FasL by 1,25(OH)₂D₃. Similar results were confirmed by Western blot assay (data not shown).

Thus, activation-induced fasL promoter activity is inhibited by 1,25(OH)₂D₃ in T cells.

To better study the role of VDR on the repression of the fasL promoter, Jurkat cells were used as a convenient cell system for transfection assays, and in agreement with the data described above, cotransfection of a human VDR expression vector was required for significant 1,25(OH)₂D₃-mediated inhibition of the fasL promoter in Jurkat cells (Fig. 4A).

Vitamin D₃ receptor heterodimerizes with the 9-cis retinoic acid receptor (called RXR), and formation of these heterodimers results in increased nuclear receptor binding in vitro and cooperation for gene activation in vivo (51). As shown in Fig. 4B, cotransfection of an RXR expression vector together with VDR further enhances the repression observed in the presence of 1,25(OH)₂D₃. Cotransfection of the RXR alone is ineffective either in the presence or in the absence of 1,25(OH)₂D₃. These data indicate that RXR cooperates in the 1,25(OH)₂D₃-mediated inhibition of the fasL promoter.

In agreement with the cell viability assay, promoter repression is regulated in a dose-dependent manner with detectable inhibition at 0.1 nM of 1,25(OH)₂D₃, and cotransfection of RXR further magnifies this effect (Fig. 5, A and B).

**Different VDR regulatory domains are involved in 1,25(OH)₂D₃-mediated fasL promoter repression: VDR DBD**

Transcriptional repression by ligand-activated nuclear hormone receptors may act through competition interference with DNA-binding factors to overlapping sequences, or by interference through direct protein-protein interaction (44, 52, 53). Moreover, several members of the nuclear receptor family, including GR, RAR/RXRs, thyroid hormone receptor (T₃ R), and VDR, interact with a number of coregulators (e.g., CREB-binding protein (CBP)/p300, SRC-1, etc.) that are required for efficient transcriptional regulation (54, 55). In this regard, competition for limiting amounts of shared coregulators may partially account for the repressive action exerted by ligand-activated nuclear receptors on several promoters (55).

To investigate the relevance of the ligand-activated VDR-DNA interaction(s) in 1,25(OH)₂D₃-mediated fasL promoter repression, mutants of the human VDR DBD within its first zinc module that abrogate specific binding to DNA (56) were used in cotransfection assay. As shown in Fig. 6A, the repression mediated by two different DBD mutants (VDR-EGG>GSV and VDR-R50>G) is greatly reduced in comparison with the VDR wild type, indicating that binding to DNA represents an important factor in this mechanism. A third mutant, VDRF (VDR-DBD G) is greatly reduced in comparison with the VDR wild type, which lacks the ligand-binding domain (LBD) and binds selectively and with high affinity to a positive vitamin D₃ response element independently of hormone (56), was also tested in cotransfection. Interestingly, repression of the fasL promoter was not observed either in the absence or in the presence of 1,25(OH)₂D₃ (Fig. 6B and data not shown), suggesting that DNA binding by itself is not sufficient for transcriptional inhibition and that other requirements are needed.

**Point mutations of the VDR that abrogate ligand-dependent interactions with transcriptional coactivators interfere with transrepression of the fasL promoter**

Nuclear receptors display a modular structure with an N-terminal region containing an activation function AF-1 (A/B domain), a region C containing the DBD, a hinge region D, and the C-terminal...
E/F region containing the LBD and the dimerization domain (57, 58). Mutational analysis of the E domain has identified a second activation-function AF-2 domain, which is critical for proper ligand-dependent activation by nuclear receptors (58). It has been proposed that upon specific ligand binding, nuclear receptors may reconfigure particular surface features of the LBD. A conformational change in helix 12, together with other changes such as bending of helix 3 in the LBD, creates a surface that allows an efficient recruitment of coactivator proteins that participate to the efficient assembly of the transcriptional apparatus (59). They include related family members such as SRC-1/NCaA1, TIF-2/GRI/1, and ACTR/pCIP. Moreover, ligand-activated transcription by nuclear hormone receptors appears to require the CBP/p300 cointegrator, which interacts directly with and is a required component common to the coactivator complexes of several nuclear receptors and general transcription factors (54, 55, 59).

To investigate whether the observed 1,25(OH)2D3/VDR-mediated inhibition of the fasL promoter was due to a possible interference between ligand-activated recruitment or sequestration of shared transcriptional coactivators by VDR, different point mutants of

---

**FIGURE 3.** The 1,25(OH)2D3 represses fasL promoter activation. A and B, 2B4.11 and Jurkat T cells were cotransfected with 15 μg of pFasL-486Luc or pFasL-486Gal, plus 3 μg of pEQ176 CMV-β-Gal expression vector or RSV-luc expression vector, respectively, as described in Materials and Methods. Twenty-four hours after transfection, cells were stimulated with 20 ng/ml PMA and 0.5 μg/ml ionomycin in the absence or in the presence of 20 nM of 1,25(OH)2D3. After 24 h, cells were harvested and protein extracts were prepared for the luciferase and β-galactosidase assays. Results are expressed as relative luciferase or β-galactosidase activity normalized to protein concentration as well as to β-galactosidase or luciferase activity produced off the internal control plasmid, and represent the mean value (X ± SE) from at least four experiments.

C and D, EMSA was performed using the 32P-labeled murine VDRE oligonucleotide as a probe in the presence of nuclear extracts (10 μg), from unstimulated (−) or PMA/ionomycin-treated 2B4.11 and Jurkat cells (4 h) in the absence or in the presence of 20 nM of 1,25(OH)2D3. Where indicated, 100 ng specific or nonspecific cold competitor, purified anti-VDR, or a nonspecific Ab was added to the reaction mixture to confirm specificity. Arrows represents the DNA binding of VDRE-specific complexes.
the human VDR within its AF-2 domain or a point mutant in the helix 3 of the LBD that abrogate normal recruitment of specific coactivators (60, 61) were used in cotransfection assay. As shown in Fig. 7, A and B, the repression mediated by these different mutants (VDR-L417>A, VDR-E420>A, and VDR-K246>A) is reduced in comparison with the VDR wild type. Although these VDR mutants are transcriptionally inactive, they maintain a correct conformation, the same ability to form heterodimers with RXR, and can bind the ligand and the DNA with affinities similar to the VDR wild type (60), indicating that competition for limiting amounts of shared coactivators might be one of the mechanisms involved in fasL promoter repression.

Ligand-activated VDR heterodimerizes with RXR, which also possesses an AF-2 domain involved in transcriptional activation. In this regard, C-terminally truncated RXRs function as dominant-negative partners in VDR-mediated transactivation (62). It has been proposed that 1,25(OH)2 D3-occupied VDR-RXR heterodimers can elicit maximal transcriptional stimulation via AF-2s of both receptors, and allosteric modulation of RXR-AF-2 domain by 1,25(OH)2 D3 (considered here as 100%), and represent the mean value (X ± SE) from at least four experiments. B, Jurkat T cells were cotransfected with 15 μg of pFasL-486Gal reporter vector plus 3 μg of the indicated expression vector(s) (pCMV-hVDR and/or pSG-hRXRα) and 3 μg of RSV-luc. Results are shown as described in A. The mean relative β-galactosidase activity of PMA plus ionomycin-activated cultures in the absence of 1,25(OH)2 D3 was: 760 and 1000 (A); 785 and 630 (B).

the data shown in Fig. 4B, cotransfection of RXR together with VDR enhances fasL promoter repression in the presence of 1,25(OH)2 D3. Cotransfection of the RXR-T454 or RXR-T448 AF-2 deletions (64) potentiated repression to a similar extent, indicating that RXR cooperates in the 1,25(OH)2 D3-mediated repression of the fasL promoter with a mechanism independent of its AF-2 domain, and that only the AF-2 domain of VDR plays a functional role in this mechanism.

Progressive deletions of the fasL promoter delineate a minimal region for 1,25(OH)2 D3-mediated inhibition

To investigate the possible presence of fasL promoter region(s) involved in the repression mediated by 1,25(OH)2 D3/VDR, we analyzed the activity of internal mutations and progressive deletions of the fasL promoter by transient transfection assay, in the presence of a VDR expression vector. Transfection of fasL promoter constructs bearing internal mutations that abrogate binding of critical transactivators such as ΔNF-AT-Dist. (for NF-AT) or...
RE3/FLRE (for EGR-3) considerably decreased the inducible activation following stimulation with PMA plus ionomycin in our experiments, as already described (28, 29, 50). However, the specific repression of residual promoter activity by 1,25(OH)2 D3 was not significantly altered in comparison with the wild-type fasL promoter vector (Fig. 8A). In this context, the activation of triplicated copies constructs of the NF-AT-Dist. or the RE3/FLRE binding sites (28, 29) was not inhibited by 1,25(OH)2 D3 (Fig. 8B), indicating that these enhancer elements are not direct targets for the 1,25(OH)2 D3/VDR-mediated repression, at least in these experimental conditions.

By using progressive deletions, we could delineate a minimal promoter fragment spanning nucleotides from +195 bp immediately 5’ of the translational start site, which is still sensitive to the 1,25(OH)2 D3 treatment in activated Jurkat cells, although to a lesser extent than the fragment from −453 bp 5’ of the translational start site (Fig. 8C).

Several studies have recently shown that the promoter fragment from −195 to +1 bp of the fasL promoter contains a major transcription initiation site at −181 bp from the first ATG (32), a NF-κB/SP-1 binding site located at −155 bp from the first ATG (65), and a noncanonical c-Myc-binding element localized in a position originally described as a putative TATA-box sequence (25).
Because 1,25(OH)\textsubscript{2}D\textsubscript{3} can modulate the activity and/or the expression of transcription factors such as NF-κB or c-Myc (24, 45, 49), we investigated whether 1,25(OH)\textsubscript{2}D\textsubscript{3}/VDR might interfere with the function of these transcription factors as regulators of the fasL promoter. To this purpose, nuclear extracts from 2B4.11 cells activated (4 h) in the presence or in the absence of 20 nM of 1,25(OH)\textsubscript{2}D\textsubscript{3} were analyzed with \textsuperscript{32}P-labeled probes encompassing the FasL-MycRE (human FasL gene, −139 to −110 bp) (25) and the FasL-NF-κB prox. (human FasL gene, −162 to −135 bp) (65).

The EMSA analysis shown in Fig. 9, A and B, indicates that constitutive and inducible specific DNA-binding complexes are detected, and competed by unlabeled oligonucleotides containing a canonical E-box/c-Myc-binding sequence (consensus Myc) or a consensus NF-κB-binding sequence (NF-κB-HIV-1 LTR), respectively. In these conditions, treatment with 1,25(OH)\textsubscript{2}D\textsubscript{3} does not modify the constitutive or the inducible c-Myc and NF-κB-binding activity to these regulatory elements. In contrast, overexpression of c-Myc, but not c-Rel, gave a significant relief (∼30%) of the 1,25(OH)\textsubscript{2}D\textsubscript{3}/VDR-mediated repression in Jurkat cells (Fig. 9, C and D), indicating that 1,25(OH)\textsubscript{2}D\textsubscript{3}/VDR may limit the transcriptional function of c-Myc in the context of the whole fasL promoter.

Repression was only partially relieved by c-Myc overexpression also when the amount of c-Myc expression vector cotransfected was increased (data not shown), suggesting that additional inhibitory mechanism(s) may take place during activation. Overexpression of p65/RelA and/or p50/NF-κB family members gave results similar to c-Rel (data not shown).

**Discussion**

In the last few years, a great deal of attention has focused on the role of Fas receptor and its ligand FasL, in the maintenance of lymphocyte homeostasis, and regulation of immune responses (1–3). Although Fas-mediated activation-induced programmed cell death represents an important mechanism to ensure self-tolerance through the elimination of activated autoreactive lymphocytes, the Fas/FasL system may also contribute to the pathogenesis of several organ-specific autoimmune diseases, through effector cells that cause direct tissue damage via activation of the Fas apoptotic pathway (7, 66). In this context, activated self-reactive T cells kill Fas\textsuperscript{+} target cells by direct lysis, and cause cell damage in other surrounding Fas\textsuperscript{+} bystander cells. In this way, infiltrating T cells may kill several MHC-negative targets (e.g., pancreatic β cells or oligodendrocytes in the nervous system) and expand local damage (7). Thus, it is becoming increasingly evident that an improperly regulated Fas-FasL system could represent a serious danger for the organism, and particularly during the onset of autoimmune diseases (7).

Several reports have shown that activation of the fasL gene and programmed cell death can be specifically inhibited by ligands that activate nuclear hormone receptors such as corticosteroids or retinoids in T lymphocytes (35–38). In this regard, gene regulation by ligand-activated nuclear receptors represents an important subject of immunopharmacology, and several studies have demonstrated that different hormones or specific ligands, such as retinoids, corticosteroids, peroxisome proliferator-activated receptor activators, or vitamin D\textsubscript{3}, are able to exert profound regulatory effects on the physiology of the immune system and during inflammatory reactions (23, 24, 40–49).

Previous work from other laboratories and our group has identified several cytokine genes as direct target of 1,25(OH)\textsubscript{2}D\textsubscript{3}/VDR-mediated repression in activated T lymphocytes, and has contributed to explain the molecular basis of the immunosuppressive effects of this hormone. IL-2, GM-CSF, and IFN-γ represent important genes repressed by 1,25(OH)\textsubscript{2}D\textsubscript{3} (23, 46–48, 56). Moreover, a direct inhibition of IL-12 production by 1,25(OH)\textsubscript{2}D\textsubscript{3} has been described in activated macrophages and DC, with a repressive effect induced by VDR/RXR on IL-12 p40 expression and...
promoter activation (24). Furthermore, 1,25(OH)₂D₃ can also block APC-dependent T cell activation by inhibiting optimal differentiation, activation, and survival of DC (15, 16).

In this study, we propose a novel molecular target of the 1,25(OH)₂D₃ action in T cells, FasL.

The results shown in the present study indicate that fasL gene expression is repressed by 1,25(OH)₂D₃ in activated T lymphocytes. Activation-induced apoptosis in 2B4.11 T cells is significantly inhibited by 1,25(OH)₂D₃, as demonstrated by PI uptake and Annexin-V/PI staining, followed by FACS analysis. The inhibition correlated...
with decreased levels of fasL mRNA expression, as demonstrated by Northern blot analysis. Moreover, by EMSA and transient transfection experiments in 2B4.11 and Jurkat T cells, we have demonstrated a direct inhibitory action of the 1,25(OH)₂D₃/VDR on the fasL promoter activation. Our data indicate that formation of VDR-RXR heterodimers and a functional VDR-DDB are two important requirements for the repression of the fasL promoter by 1,25(OH)₂D₃. However (Fig. 6B), DNA binding alone is not sufficient for transcriptional inhibition, and different point mutations within the VDR AF-2 domain (helix 12) or a point mutant in the helix 3 of the LBD that abrogate recruitment of transcriptional coactivators (60) indicate that competition for limiting amounts of specific common coactivators is also involved in fasL promoter repression.

Interestingly, transfection of fasL promoter internal mutations that abrogate binding of critical transactivators, such as ΔNF-AT-Dist. and ΔRE3/FLRE (28, 29), did not significantly alter the specific repression of residual promoter activity (Fig. 8A). Moreover, the activation of triplicated copies constructs of the FasL-NF-AT-Dist. or the FasL-RE3/FLRE binding sites (28, 29) was not altered by 1,25(OH)₂D₃ (Fig. 8B), suggesting that these enhancer elements are not direct targets for the 1,25(OH)₂D₃/VDR-mediated repression, at least in our experimental conditions. By using progressive deletions, we could identify a minimal promoter fragment spanning nucleotides from −195 bp immediately 5’ of the transcriptional start site that is still repressed by 1,25(OH)₂D₃. This promoter fragment contains a major transcription initiation site at −181 bp from the first ATG (32), a NF-κB/SP-1 binding site located at −155 bp from the first ATG (65), and a novel noncanonical c-Myc-binding element that overlaps a position originally described as a putative TATA-box sequence (25).

The involvement of NF-κB and c-Myc in fasL gene regulation has been extensively studied in the last few years. c-Myc has been shown to contribute to cell death in AICD of T cell hybridomas (2), to directly activate the fasL promoter (2, 25, 33), and represents a specific target for the TGF-β1-mediated inhibition of FasL expression and AICD in T cells (34). Differently, although NF-κB-dependent regulation of fasL gene and promoter activity has been described in different models (2, 65), recent experimental observations obtained using inhibitor of κB (IκB)-kinase γ-deficient T cells have shown that NF-κB-signaling defects have no effect on mitogen-stimulated expression of fasL mRNA or activation of the fasL promoter (67).

In activated T lymphocytes, both NF-κB and c-Myc are important targets for the inhibitory activity of 1,25(OH)₂D₃/VDR (45, 49), and in our cotransfection assays overexpression of c-Myc, but not c-Rel, could significantly relieve the 1,25(OH)₂D₃/VDR-mediated repression, indicating that 1,25(OH)₂D₃/VDR may interfere with the transcriptional function of c-Myc and alter optimal activation of the fasL promoter. The inhibition was only partially relieved, even when we used increased amounts of c-Myc expression vector cotransfected (data not shown), suggesting that additional inhibitory mechanism(s) may take place in this system.

Much evidence has indicated that nuclear receptors, including VDR, recruit specific coactivator proteins necessary for efficient transcriptional regulation. They include related family members such as SRC-1/NCoA1, TIF-2/GRIP-1, and ACTR/pCIP (54, 59). Furthermore, ligand-activated transcription by nuclear hormone receptors appears to require the CBP/p300 cointegrator, an essential component in the formation of active complexes with several nuclear receptors and general transcription factors (54, 55, 59). These observations have suggested that nuclear receptors (e.g., GR or RAR/RXRs) might compete for limiting cellular pools of common transcriptional cofactors and/or adapter-integrators, normally required for an optimal activity of specific transcription factors in a promoter (44, 53–55, 59).

Our transfection experiments indicate that fasL promoter repression mediated by VDR mutants that abrogate normal recruitment of specific coactivators (VDR-L417→A, VDR-E420→A, and VDR-K246→A) (60) is greatly reduced in comparison with the VDR wild type (Fig. 7), and that competition for limiting amounts of common coactivators might be involved in this model.

In this regard, the observation that 1,25(OH)₂D₃ does not modify c-Myc-binding activity to the FasL-MycRE regulatory element in 2B4.11 cells, and that overexpression of c-Myc may partially relieve 1,25(OH)₂D₃/VDR-mediated repression may suggest a mechanism of competition for a specific factor.

Additional experiments will be necessary to identify the limiting factor(s) that might be sequestered in activated T lymphocytes through this mechanism, and that coregulates fasL promoter activity.

On the contrary, overexpression of C-terminally (AF-2 domain) truncated RXR (RXR-T454 and RXR-T448) increased repression, as observed with the wild-type RXR, suggesting that RXR cooperates with ligand-bound VDR through a mechanism independent of its AF-2 domain function. An augmented nuclear import (68) and heterodimer formation (51) that enhance specific nuclear receptor binding to the DNA might explain these data. In this regard, cotransfection of VDR-DDB mutants (VDR EGG→GVS and VDR-R50→G) indicated that direct binding on specific fasL promoter sequences might be involved. A sequence homology search did not reveal the presence of putative VDR-binding consensus (VDREs) in the fasL promoter, yet several reports have shown that VDR can bind with different affinities to rather degenerate consensus sequences, as shown for the IL-2, GM-CSF, and IFN-γ promoters (23, 47, 48, 56). Additional experiments will be necessary to verify this hypothesis in the fasL promoter and in particular at the level of the segment −195 bp immediately 5’ of the transcriptional start site.

The 1,25(OH)₂D₃ and a number of related nonhypercalcemic analogues have been recently evaluated as a promising category of immunosuppressive molecules that might provide new therapeutic tools for several chronic inflammatory autoimmune diseases (18–22, 69). An impairment of APC functions and a powerful ability of the Th1-type immune response by 1,25(OH)₂D₃ (also in combination with other immunomodulators such as CsA or corticosteroids) seem to play a major role in these treatments.

The 1,25(OH)₂D₃-mediated regulation of FasL might cooperate with the 1,25(OH)₂D₃-mediated inhibition of Th1 development and pathogenesis of autoimmune disorders as observed in EAE, in which inhibition of cytokines such as IL-12 and IFN-γ and systemic increase of protective Th2 cytokines such as IL-4 or TGF-β have been described, and correlates with the prevention and/or amelioration of these diseases (11, 17–20). In addition, the observation that production of IFN-γ during the progression of inflammation may generate metabolically active 1,25(OH)₂D₃ (from the precursor 25-hydroxvitamin D₃) in local macrophages also suggests a paracrine role of 1,25(OH)₂D₃ in a negative feedback loop (13, 14).

These observations, and the recent notion that reverse signaling through Fasl is required for CTLs to achieve optimal proliferation (8, 9), together with the ability of the activated Fas receptor to induce phenotypical and functional maturation of DC, and a preferential T cell polarization toward a Th1 phenotype (10), suggest that modulation of the fasL gene in T lymphocytes may represent an interesting tool for the therapy of several autoimmune disorders.
In summary, these data extend our knowledge of the complex effects mediated by 1,25(OH)_{2}D_{3} as a paracrine and pharmacological regulator of the inflammatory and immune responses, and propose FasL as a novel molecular target for the immunosuppressive action of 1,25(OH)_{2}D_{3} in T lymphocytes.

Acknowledgments
We thank Drs. Gary A. Koretzky and Carlos V. Paya for providing the human FasL promoter vectors, Dr. Christopher B. Wilson for providing the pEQT176 CMV-β-gal and the pEPO3 promoterless β-gal vector, Dr. Pierre Chambon for providing human and murine wild-type and C-terminal (AF-2) deletion mutants RXRe expression vectors, Dr. Leonard Freedman for providing expression vectors for the wild-type and the different DBD mutants of the human VDR, Dr. Mark R. Haussler for providing expression vectors for wild-type human VDR and VDR AF-2 domain mutants, Dr. Ana Arandia for human T cell CD3 domain point mutant K264A, Dr. Gabriela Zupi for providing the human M-Cys expression vector, Dr. Howard A. Young for providing the human C-Rel expression vector and the pR-SPA empty control vector, and Dr. Ruggiero De Maria for providing the Fas-transfected p815 mastocytoma cell line. We also thank Dr. Dulia Del Bel and Simona Cascioli for cytotoxicity assays, and Mr. Luigi Minervino for technical assistance.

References


